Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024)

Avalo Therapeutics filings provide 8 years of Gross Margin readings, the most recent being 186.75% for Q3 2024.

  • On a quarterly basis, Gross Margin fell 18209.0% to 186.75% in Q3 2024 year-over-year; TTM through Sep 2024 was 11.71%, a 1722.0% decrease, with the full-year FY2023 number at 33.26%, down 4771.0% from a year prior.
  • Gross Margin hit 186.75% in Q3 2024 for Avalo Therapeutics, down from 138.7% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 138.7% in Q4 2023 to a low of 186.75% in Q3 2024.
  • Median Gross Margin over the past 5 years was 32.74% (2021), compared with a mean of 23.2%.
  • Biggest five-year swings in Gross Margin: crashed -18833bps in 2021 and later surged 12441bps in 2022.
  • Avalo Therapeutics' Gross Margin stood at 94.72% in 2020, then tumbled by -199bps to 93.61% in 2021, then soared by 133bps to 30.8% in 2022, then surged by 350bps to 138.7% in 2023, then crashed by -235bps to 186.75% in 2024.
  • The last three reported values for Gross Margin were 186.75% (Q3 2024), 138.7% (Q4 2023), and 4.66% (Q3 2023) per Business Quant data.